Mr Kelvin Alan Turner, | |
10166 Foxfield Ln Apt L, Avon, IN 46123-1171 | |
(317) 371-7592 | |
Not Available |
Full Name | Mr Kelvin Alan Turner |
---|---|
Gender | Male |
Speciality | Licensed Practical Nurse |
Location | 10166 Foxfield Ln Apt L, Avon, Indiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1538430475 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164W00000X | Licensed Practical Nurse | 27036787A (Indiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mr Kelvin Alan Turner, 10166 Foxfield Ln Apt L, Avon, IN 46123-1171 Ph: (317) 371-7592 | Mr Kelvin Alan Turner, 10166 Foxfield Ln Apt L, Avon, IN 46123-1171 Ph: (317) 371-7592 |
News Archive
The one-child policy seeks to keep China's population, now 1.3 billion, at around 1.7 billion by 2050. Ethnic minorities and farmers are the only groups legally exempt from the rule.
Net sales for the first quarter of fiscal 2010 were $42,457,000 as compared to $34,293,000 for the same period of the prior fiscal year, an increase of 24%. Net earnings for the first quarter of fiscal 2010 were $8,921,000 or $0.22 per diluted share, both increases of 10% over the first quarter of fiscal 2009. Diluted common shares outstanding for fiscal 2010 and 2009 were 41,185,000 and 41,125,000, respectively.
While all names have been suppressed to protect the identities of those involved, the case has caught the imagination of the media. "Dr N" who admitted to professional misconduct before the Health Practitioners Disciplinary Tribunal was reported to have appealed to the High Court against being struck off by The Weekend Herald on Saturday. The appeal was unsuccessful.
As the number of Americans who regularly use cannabis has climbed, so too has the number of those experiencing cannabis withdrawal symptoms.
A phase 2 clinical trial for the treatment of a severe form of age-related macular degeneration called geographic atrophy (GA) has become the first study to show the benefit of a therapy to slow the progression of vision loss for this disease. The results highlight the benefit of the use of a neurotrophic factor to treat GA and provide hope to nearly one million Americans suffering from GA.
› Verified 5 days ago